Please provide your email address to receive an email when new articles are posted on . Mucosal melanoma — or melanoma in the mucous membranes — differs from cutaneous melanoma in its genesis, its ...
Scientists headed by a team at the University of Tokyo have identified a protein, known as podoplanin (PDPN), that is common to both human and canine mucosal melanoma, and which appears to mobilize ...
"There are many other factors that could possibly contribute to better or worse prognosis for patients with mucosal melanoma, including mutational status of genes like BRAF." — Kathleen M. Mulligan, ...
Although rare, mucosal melanoma in humans has a low survival rate. It has been difficult to investigate due to a lack of similar cancers in animals for study. Researchers explored a protein common to ...
Nemvaleukin alfa is an investigational, engineered fusion protein consisting of modified interleukin-2 (IL-2) and the high-affinity IL-2 alpha receptor chain. The Food and Drug Administration (FDA) ...
Although rare, mucosal melanoma in humans has a low survival rate. It has been difficult to investigate due to a lack of similar cancers in animals for study. Researchers explored a protein common to ...
The FDA granted fast track designation to nemvaleukin alfa for treatment of mucosal melanoma. Nemvaleukin alfa (Alkermes) is an investigational engineered interleukin-2 variant immunotherapy. Source: ...
A phase 2 study evaluated meaningful activity from lifileucel for patients with advanced mucosal melanoma who experienced disease progression on immune checkpoint inhibitors. Lifileucel led to ...
Not all melanomas are created equal. While most melanomas appear on the skin as the result of sun exposure, a small subset of melanomas arise spontaneously from mucosal tissues. And while targeted ...
A retrospective study on the combination of a vascular endothelial growth factor receptor inhibitor plus programmed cell death-1 blockade added to evidence of efficacy in early trials. The combination ...
This is an ASCO Meeting Abstract from the 2021 ASCO Annual Meeting I. This abstract does not include a full text component.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback